Oral contraceptive pills and possible adverse effects

LAUR Repository

Show simple item record

dc.contributor.author Stone, Rebecca H,
dc.contributor.author Rafie, Sally
dc.contributor.author El-Ibiary, Shareen Y.
dc.contributor.author Karaoui, Lamis R.
dc.contributor.author Shealy, Kayce M.
dc.contributor.author Vernon, Veronica P.
dc.date.accessioned 2016-09-30T12:27:48Z
dc.date.available 2016-09-30T12:27:48Z
dc.date.copyright 2014 en_US
dc.date.issued 2016-09-30
dc.identifier.uri http://hdl.handle.net/10725/4470
dc.description.abstract Oral contraceptive pills (OCPs) containing estrogen and progestin or progestin only were introduced as a contraceptive option for women in 1960. Since their introduction to the market, there have been significant changes in the drug content and formulations of these products, in part to decrease the risk of adverse effects. The OCP products available today, particularly combined oral estrogen and progestin products (COCs), continue to be widely used. The major adverse effect associated with COCs is an increased risk of a cardiovascular event. COCs are contraindicated for women with increased cardiovascular risk, increased thromboembolic risk, significant liver disease, systemic lupus erythematosus, or migraine with aura. In addition, both COCs and progestin-only pills (POPs) are contraindicated in patients with a personal history of breast cancer. Commonly reported minor adverse effects may include menstrual bleeding pattern changes, breast tenderness, headache, mood changes, and nausea. Frequently these minor adverse effects subside following the initial 3 months of appropriately administered therapy, and otherwise may be managed by changing the hormone strength or product formulation and confirming patient adherence. It is imperative that providers are familiar with the potential adverse effects associated with OCP use, so they may in turn educate and counsel patients. Since adverse effects are the primary reason for OCP discontinuation, it is critical that patients are made aware of and expect these in advance and are counseled how to minimize or manage adverse effects. It is important to note that many women also use OCPs for noncontraceptive benefits, such as regulating menstrual irregularities, treatment of premenstrual syndrome, prevention of menstrual migraine, treatment of acne, and others. en_US
dc.language.iso en en_US
dc.title Oral contraceptive pills and possible adverse effects en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOP en_US
dc.author.idnumber 200101817 en_US
dc.author.department Pharmacy Practice en_US
dc.description.embargo N/A en_US
dc.relation.journal Journal of Symptoms an Signs en_US
dc.journal.volume 3 en_US
dc.journal.issue 4 en_US
dc.article.pages 282-291 en_US
dc.keywords Oral contraceptive pill en_US
dc.keywords Combined hormonal contraceptive en_US
dc.keywords Progestin-only pill en_US
dc.keywords Contraception en_US
dc.keywords Adverse effects en_US
dc.identifier.ctation Stone, R. H., Rafie, S., El-Ibiary, S. Y., Karaoui, L. R., Shealy, K. M., & Vernon, V. P. (2014). Oral contraceptive pills and possible adverse effects. Journal of Symptoms and Signs, 3(4), 282-291. en_US
dc.author.email lamis.karaoui@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.orcid.id https://orcid.org/0000-0002-7857-7374

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account